THE RELATIONSHIP BETWEEN PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND INSULIN-RESISTANCE IN NEWLY-DIAGNOSED TYPE-2 DIABETES-MELLITUS

被引：34

作者：

GOUGH, SCL ^{[1
]}

RICE, PJS ^{[1
]}

MCCORMACK, L ^{[1
]}

CHAPMAN, C ^{[1
]}

GRANT, PJ ^{[1
]}

机构：

[1] GEN INFIRM,ACAD UNIT MED,G FLOOR,MARTIN WING,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND

来源：

DIABETIC MEDICINE | 1993年 / 10卷 / 07期

关键词：

TYPE-2; DIABETES-MELLITUS; PLASMINOGEN ACTIVATOR INHIBITOR-1; INSULIN RESISTANCE;

D O I：

10.1111/j.1464-5491.1993.tb00137.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

It is not clear whether elevated levels of the fibrinolytic inhibitor, plasminogen activator inhibitor-1 (PAI-1) in Type 2 diabetes mellitus are the result of obesity or coexistent atherosclerosis. Therefore the relationship between PAI-1 and insulin resistance, determined by the homeostasis model assessment (HOMA) was investigated in a group of 26 insulin-resistant, normotensive newly diagnosed Type 2 diabetic patients with a low probability of atherosclerosis. Compared with a normal control group, closely matched for body mass index (BMI), fibrinolytic activity was depressed in the diabetic patients due to elevated levels of the inhibitor PAI-1, 17.6 (11.1-28) vs 8.4 (4.9-14.1) IU ml-1, p < 0.001. PAI-1 was related to BMI, r = 0.59, p < 0.001 plasma insulin, r = 0.66, p < 0.001; insulin resistance, r = 0.54, p < 0.005 and urinary albumin excretion, r = 0.48, p < 0.01, but not HbA1c or fasting glucose. PAI-1 was not related to blood pressure or plasma triglyceride levels. This study suggests that at the time of diagnosis of Type 2 diabetes mellitus, elevated PAI-1 levels are already linked to other risk factors for vascular disease including hyperinsulinaemia, insulin resistance, and urinary albumin excretion, and this is not the result of obesity or coexistent atherosclerosis.

引用

页码：638 / 642

页数：5

共 28 条

[1]

Kruithof EKO., Plasminogen activator inhibitors—a review, Enzyme, 40, pp. 113-121, (1988)

[2]

Hamsten A., Wiman B., Defaire U., Blomback M., Increased plasma level of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction, N Engl J Med, 313, pp. 1557-1563, (1985)

[3]

Hamsten A., Defaire U., Waldius G., Dahlen G., Szamosi A., Landou C., Et al., Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction, Lancet, 2, pp. 3-9, (1987)

[4]

Vague P., Juhan-Vague I., Aillaud MF, Badier C., Viard R., Alessi MC, Et al., Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects, Metabolism, 35, pp. 250-253, (1986)

[5]

Landkin K., Tengborn L., Smith U., Elevated fibrinogen and plasminogen activator inhibitor (PAI‐1) in hypertension are related to metabolic risk factors for cardiovascular disease, Journal of Internal Medicine, 227, pp. 273-278, (1990)

[6]

Auwerx J., Bouillon R., Collen D., Geboers J., Tissue‐type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus, Arteriosclerosis, 8, pp. 68-72, (1988)

[7]

Walsmsley D., Hampton KK, Grant PJ., Contrasting fibrinolytic responses in Type 1 (insulin‐dependent) and Type 2 (non‐insulin‐dependent) diabetes, Diabetic Medicine, 8, pp. 954-959, (1991)

[8]

Juhan-Vague I., Alessi MC, Vague P., Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis, Diabetologia, 34, pp. 457-462, (1991)

[9]

Gough SCL, Grant PJ., The fibrinolytic system in diabetes mellitus, Diabetic Med, 8, pp. 898-905, (1991)

[10]

(1980)

← 1 2 3 →